News & Updates

Show Multimedia Only

AVAPS‐AE, ST ventilation show similar impact on sleep quality in OHS patients

28 Sep 2020

Two months of average volume‐assured pressure support—automated expiratory positive airway pressure (AVAPS‐AE) is comparable to pressure support (ST) ventilation in terms of effect on sleep quality and gas exchange among patients with obesity hypoventilation syndrome (OHS), a recent study has shown.

AVAPS‐AE, ST ventilation show similar impact on sleep quality in OHS patients

28 Sep 2020

Dupilumab cuts exacerbation rates in patients with asthma regardless of lung function

28 Sep 2020 by

Patients with moderate-to-severe asthma had significant reductions in annualized severe asthma exacerbation rate with the monoclonal antibody dupilumab, regardless of lung function, according to a post hoc analysis of LIBERTY ASTHMA QUEST* presented at ERS 2020.

Dupilumab cuts exacerbation rates in patients with asthma regardless of lung function

28 Sep 2020

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

25 Sep 2020 by

Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

25 Sep 2020

Single-dose nirsevimab prevents RSV-associated LRTI in preterm infants

25 Sep 2020 by

A single-dose of nirsevimab helps prevent respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in preterm infants during an entire RSV season, according to a recent study.

Single-dose nirsevimab prevents RSV-associated LRTI in preterm infants

25 Sep 2020

Nivolumab-ipilimumab displays potential in malignant pleural mesothelioma

24 Sep 2020 by

For patients with unresectable malignant pleural mesothelioma (MPM), nivolumab plus ipilimumab in the first-line setting demonstrated greater overall survival (OS) than standard-of-care (SoC) platinum chemotherapy, interim analysis of the phase III CheckMate743 trial revealed.